The Nordic region—historically celebrated as a powerhouse of life sciences, medical research, and biotechnology innovation—is currently confronting a complex economic…
Read More
Looking beyond short-term turmoil, Syngene is investing for the future – Pharmaceutical Technology
The global contract research, development, and manufacturing organization (CDMO) sector is undergoing a profound structural evolution, driven by shifting supply…
Read More
UK and Switzerland Forge Landmark Free Trade Agreement, Cementing Pharmaceutical Intellectual Property Protections
The United Kingdom and Switzerland have finalized a groundbreaking free trade agreement that explicitly enshrines intellectual property (IP) protections for…
Read More
J&J raises FY26 outlook following positive Q2 – Pharmaceutical Technology
Johnson & Johnson (J&J) announced robust second-quarter (Q2) revenues totaling approximately $25.3 billion, marking a significant 6.6% increase year-over-year (YoY).…
Read More
The Crucial Role of Data Reliability in Early-Phase Clinical Trials for Pharmaceutical Development
In the intricate landscape of pharmaceutical research and development, the integrity of data generated during early-phase clinical trials serves as…
Read More
AI Transforms Pharmaceutical Regulatory Submissions: Predictive Intelligence and End-to-End Pipelines Emerge as Game-Changers
The pharmaceutical industry is undergoing a profound transformation driven by the rapid integration of Artificial Intelligence (AI), moving beyond early-stage…
Read More
EHA26: J&J’s multiple myeloma therapies impress with new data – Pharmaceutical Technology
The European Hematology Association (EHA) 2026 conference, held from June 11th to 14th in Stockholm, Sweden, served as a pivotal…
Read More
Simcere Pharmaceutical Group Partners with Stanford Medicine to Pioneer Novel Therapies for Idiopathic Pulmonary Fibrosis
Simcere Pharmaceutical Group has forged a significant research collaboration with Stanford Medicine, aiming to unlock novel therapeutic avenues for idiopathic…
Read More
Pharmaceutical R&D Returns Soar to 7% Driven by GLP-1 Blockbusters, Raising Sustainability Questions for the Industry
After a period characterized by uneven growth and strategic recalibrations in the wake of global health challenges, a key metric…
Read More
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma – Pharmaceutical Technology
The rapidly evolving landscape of multiple myeloma treatment is witnessing a pivotal moment with the emergence of in vivo chimeric…
Read More
